Adult-onset Still'
Conditions
Interventions
None listed
Sponsors
Yokohama City University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)The published study including case-control study, cohort study, and randomized clinical trial. (2)The patients are clinically diagnosed with AOSD. (3)The experimental group of the study is treated by biologics, with or without control treatment arm. (5)The study illustrates the safety of biologics. (6)Only full-text papers are used to analyze.
Exclusion criteria
Exclusion criteria: (1)Systematic review or meta-analysis articles. (2)Case reports or case series reporting less than 5 cases. (3)The republished research literature is excluded unless the research includes new findings related to adverse events listed in inclusion criteria. (4)Studies with no or insufficient safety results at the time of the literature search. (5)Studies published in languages other than English.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome: The prevalence of MAS will be pooled using random effects model meta-analysis. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcome: The frequency of serious adverse events will be pooled using random effects model meta-analysis. | — |
Countries
Japan
Contacts
Public ContactKaoru Minegishi
Yokohama City University Graduate School of Medicine Department of Stem Cell and Immune Regulation
Outcome results
None listed